Locus Biosciences—a clinical-stage biotech developing a new class of CRISPR-based antibacterial drugs—just closed a $35 million financing round with backing from Johnson & Johnson. The $35 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback